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Manipulation of dystrophin pre-mRNA processing oﬀers the potential to overcome mutations in the dystrophin gene that would
otherwise lead to Duchenne muscular dystrophy. Dystrophin mutations will require the removal of one or more exons to restore the
reading frame and in some cases, multiple exon skipping strategies exist to restore dystrophin expression. However, for some small
intra-exonic mutations, a third strategy, not applicable to whole exon deletions, may be possible. The removal of only one frame-shifting
exon ﬂanking the mutation-carrying exon may restore the reading frame and allow synthesis of a functional dystrophin isoform,
providing that no premature termination codons are encountered. For these mutations, the removal of only one exon oﬀers a simpler,
cheaper and more feasible alternative approach to the dual exon skipping that would otherwise be considered. We present strategies to
by-pass intra-exonic dystrophin mutations that clearly demonstrate the importance of tailoring exon skipping strategies to speciﬁc
patient mutations.
Crown Copyright  2011 Published by Elsevier B.V.
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Antisense oligomer (AO) mediated exon skipping is a
promising therapeutic approach for Duchenne muscular
dystrophy (DMD), with rescue of functional dystrophin
isoforms demonstrated in mouse and canine models of
muscular dystrophy [1–3], including the severely aﬀected
utrophin:dystrophin deﬁcient (dko) mouse [4]. Successful
proof-of concept clinical studies using two diﬀerent
oligomer chemistries have been reported in DMD patients
[5–8]. These trials have demonstrated that direct intramus-0960-8966Crown Copyright  2011 Published by Elsevier B.V.
doi:10.1016/j.nmd.2011.10.007
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Open access undcular injection or systemic delivery of two diﬀerent oligo-
mers, to DMD patients with amenable mutations, could
excise dystrophin exon 51, thereby restoring the reading-
frame and result in expression of correctly localised Becker
muscular dystrophy (BMD)-like dystrophin isoforms.
Exon skipping is most commonly considered for read-
ing-frame restoration around genomic whole exon dele-
tions, as these represent the most common type of DMD
mutation. Although there are two deletion hotspots in
the DMD gene [9], other more subtle DMD mutations,
including nonsense mutations, splice motif defects and
intra-exonic insertions or deletions (indels) are spread
across the gene. The nature and location of the mutation
will dictate the splice switching strategy required to address
diﬀerent mutations, with in silico prediction tools facilitat-
ing exon skipping strategy selection [10]. It is generally
assumed that the most appropriate strategy will also beer CC BY license.
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exons to restore the reading frame. However, other factorsTable 1
Intra-exonic mutations in frame-shifting exons in the DMD gene that
could respond to alternative exon skipping strategies.
Intra-exonic defect Strategy 1 Strategy 2
Mutation in exon 7 Skip 6 + 7 + 8 Skip 2–7
Mutation in exon 20 Skip 19 + 20 Skip 20 + 21
Mutation in exon 44 Skip 43 + 44 Skip 44 + 45
Mutation in exon 45 Skip 44 + 45 Skip 45 + 46
Mutation in exon 51 Skip 50 + 51 Skip 51 + 52
Mutation in exon 52 Skip 51 + 52 Skip 52 + 53
Mutation in exon 55 Skip 54 + 55 Skip 55 + 56
Mutation in exon 56 Skip 55 + 56 Skip 56 + 57
Mutation in exon 63 Skip 62 + 63 Skip 63 + 64 + 65
Mutation in exon 66 Skip 65 + 66 Skip 66 + 67 + 68
Mutation in exon 68 Skip 68 + 69 Skip 69 + 70
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frame, stop codons induced by a 2 base shift are shown by an arrow head bemust be taken into account, including the eﬃciency of indi-
vidual exon removal, and in cases where there are alterna-
tive options (Table 1), the predicted functionality of the
induced dystrophin isoforms. For example, a frame-shift-
ing deletion of exon 51 may be addressed by removal of
either exon 50 or 52. If both exons can be removed with
similar eﬃciency, then target selection should be deter-
mined by the functionality of the resultant protein. The
removal of exons 51 and 52 would retain a portion of hinge
3, while excision of exons 50 and 51 will remove the entire
hinge. It is yet to be determined which of these dystrophin
isoforms would retain the greatest functionality, though
patients have been documented with a deletion of exons
50 and 51, presenting with a mild BMD phenotype [11].
Studies are currently ongoing to assess dystrophin isoform
function based upon exon boundaries [12] and structure of
intact or partial spectrin repeats in the rod domain [13–15].7 8 9 10
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ing isoforms, then, applicability to other mutation subtypes
could be considered; skipping exon 50 or 52 could beneﬁt
5.2% and 4.0% of DMD deletions, respectively [16]. Also,
potential single nucleotide polymorphisms (SNPs) located
within AO binding sites that may aﬀect oligomer annealing
must also be considered.
Thirty-nine of the seventy-seven “skippable” dystrophin
exons (Fig. 1), if one excludes the ﬁrst and last exon, can be
removed individually without compromising the reading
frame (Table 2). DMD-causing mutations conﬁned to most
of these in-frame exons are typically intra-exonic, and
include nonsense mutations, splice site defects and small
insertions/deletions (indels) that disrupt the reading frame,
resulting in premature termination of translation. Conse-
quently, these mutations, spread across approximately half
of the gene could be removed from the mature dystrophin
mRNA by single exon excision [1,17–19].
Intra-exonic mutations within frame-shifting exons will
normally require two or more exons to be excised, the
lesion-carrying exon and a ﬂanking exon(s) to maintain
the reading frame. Some such cases present alternative
options in that either of the ﬂanking exons may be excised
(Table 1). However, particular mutations at or near splice
sites present a third, simpler option where only one exon
need be excluded to restore the reading frame. These
selected mutations, typically located near the exon bound-
aries, may allow the mutated exon to remain in place while
the ﬂanking, frame-shifting exon is excised to restore the
reading frame. The nature of the mutation creates a new
reading frame, and provided that no stop codons are cre-
ated between the lesion and the novel exon junction, these
mutations can be addressed by single exon removal. This
option oﬀers a minimalist exon skipping strategy and max-
imises retained dystrophin coding sequence.
Although promising results have been reported for the
Phase 2 exon 51 clinical trials using the morpholino oligo-
mer AVI-4658 [8], unequivocal therapeutic beneﬁts have
yet to be demonstrated. Long-term safety and tolerability
to the antisense oligomers must be demonstrated and exon
skipping is likely to be implemented into the clinic in
stages, and it is probable that dual exon skipping would
be delayed until single exon skipping has been well estab-
lished. The strategy reported here may expedite the appli-
cation of AO induced exon skipping to selected DMD
patients.Table 2
In-frame exon blocks that may be removed from the dystrophin transcript tha
In-frame exon
combinations
Dystrophin exons
Single 3, 4, 5, 9, 10, 13, 14, 15, 16, 23–42, 47, 48, 49,
Two exons 11–12, 17–18, 19–20, 20–21, 21–22, 43–44, 44–4
68–69, 69–70
Three exons 6–8, 59–61, 62–64, 63–65, 64–66, 66–68, 76–78
Larger in-frame blocks Deletion of exon 2 restored by 3–7 skipping, de2. Materials and methods
2.1. Antisense oligomer design and synthesis
Splice switching AOs, designed to excise human dystro-
phin exons, have been described previously [20–22]. 20-O-
methyl modiﬁed bases on a phosphorothioate backbone
(2OMeAOs) were prepared on an Expedite 8909 Nucleic
acid synthesiser using the 1 lM thioate synthesis protocol.
The compounds described here target normal dystrophin
exons 19, 20, 21, 22, 50, 51 and 52 and are designed to
anneal to splicing motifs at the intron/exon boundaries,
as well as exonic splice enhancer (ESE) motifs predicted
by the web based application, ESEﬁnder [23]. These AOs
had been previously optimised and evaluated for inducing
speciﬁc exon skipping after transfection into normal myo-
genic cells [21,22].
2.2. Primary human myoblast and ﬁbroblast propagation
All patient biopsy samples were collected with informed
consent and de-identiﬁed. The use of human tissue was
approved by the University of Western Australia Human
Ethics Committee (approval number RA/4/1/2295). Myo-
genic cells were propagated as previously described [24].
Fibroblast cultures were propagated from skin biopsies as
previously described [25]. Prior to transfection with AOs,
normal myogenic cells were plated at conﬂuent density
and allowed to diﬀerentiate for 1–3 days in low serum med-
ium, prior to transfection. Fibroblast cultures were ﬁrst
transformed to a myogenic lineage with a MyoD express-
ing adenoviral vector (The Native Antigen Company,
Oxford, UK) [26], at an MOI of 200 and allowed to diﬀer-
entiate for 2–3 days, once multinucleated myotubes were
observed, prior to transfection.
2.3. Sequencing and splice site prediction
Genomic DNA was isolated using Trizol reagent as per
the manufacturer’s instructions (Invitrogen, Melbourne,
Australia). PCR amplicons were isolated for sequencing
using the band stab protocol [27] and sequenced at the
Australian Genome Research Facility (Perth node).
Sequence analysis was performed using VectorNTI soft-
ware (Invitrogen). Patient mutations are summarised in
Table 3. Exonic splice enhancers sites found in normalt may be involved in by-passing protein truncating mutations.
60, 64, 71, 72, 73, 74, 77
5, 45–46, 50–51, 51–52, 52–53, 54–55, 55–56, 56–57, 58–59, 62–63, 65–66,
letion of 75 restored by skipping 70–75
Table 3
DMD patient mutations compared to human dystrophin mRNA sequence (NM_000109.3) and genomic sequence (NG_012232.1).
Patient sample Mutation Location Result
A c7348dupG Exon 51 – Intra exonic Frame shift
B c2601-2602delAA Exon 20 – Intra exonic Frame shift
C c2568-2575delACCCACCA Exon 20 – Intra exonic Frame shift
D c2804-2C>G Exon 22 – Acceptor splice site 1 bp of intron 21 retained
E c2623-3C>G Exon 21 – Acceptor splice site 2 bp of intron 20 retained
300 C.F. Adkin et al. /Neuromuscular Disorders 22 (2012) 297–305and mutated DMD transcripts were predicted using ESE-
Finder3(c) [28]. Splice site scores were predicted using the
alternative exon calculator tool from the Zhang Group at
Cold Spring Harbour laboratories, http://www.rulai.csh-
l.edu/new_alt_exon_db2/HTML/score.html.
2.4. Antisense oligomer transfection and RT-PCR analysis
2OMeAOs were transfected into diﬀerentiated myotubes
in Opti-MEM (Invitrogen) as cationic lipoplexes with Lipo-
fectamine 2000 reagent at 1:1 w:w ratio, according to the
manufacturer’s instructions (Invitrogen). Concentrations
stated are total AO concentrations, where a cocktail of
AOs is used; the concentration is the total of all AOs at 1:1
ratio. AOs used are listed in Supplementary Table 1. Trans-
fected cells were incubated for 24–48 h before total RNA
extraction using Trizol reagent according to the manufac-
turer’s instructions (Invitrogen) and RT-PCR was carried19 20
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Fig. 2. Skipping of exon pairs in normal human myogenic cultures. (A) Loca
Nested RT-PCR across exons 17–25 showing skipping of pairs of exons with AO
AO concentrations of 600–25 nM. Marker is a 100 bp ladder. Full-length (FL
832 bp and D21&22 transcript is 928 bp. (E) Locations of AO annealing sites in
55 showing skipping of pairs of exons with AO cocktails targeted to exons (F) 5
a 100 bp ladder. Full length (FL) transcript is 1087 bp, D50&51 transcript is 7out as previously described by nested RT-PCR [29]. RT-
PCR products were separated by agarose gel electrophoresis
with 100 bp DNA ladder (Invitrogen). Ampliﬁcation and
sequencing primers used are listed in Supplementary Table
2. All transfection and RT-PCR analyses were carried out
a minimum of two times.
3. Results
3.1. Conﬁrming eﬃcacy of AO cocktails in normal human
myogenic cells
Before AOs were transfected into cells from DMD
patients, their eﬃcacy was conﬁrmed in normal human
myogenic cells (Fig. 2). Cocktails of AOs to skip exons
19&20, exons 20&21 and exons 21&22 showed that each
pair of exons could be eﬃciently removed at the lowest con-
centration tested of 25 nM. There was little diﬀerence in eﬃ-21 22
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human dystrophin exons 50, 51 and 52. Nested RT-PCR across exons 48–
0&51 and (G) 51&52 at total AO concentrations of 600–2.5 nM. Marker is
45 bp and D51&52 transcript is 736 bp.
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was more eﬀective at the higher concentrations of 200–
600 nM. Skipping of exons 50 + 51 was induced at a con-
centration of 5 nM, and was marginally more eﬀective than
skipping exon 51&52, which could only be detected in cells
treated with 25 nM of AO and not at lower concentrations.
3.2. Alternative strategies to address intra-exonic mutations
Here we present three examples of disease-causing intra-
exonic mutations in the DMD gene. One in exon 51,
(Patient A, c7348dupG) a single G duplication and two in2118
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and skipping of exons 20&21 in (J) in 2 base deletion cells and (L) 8 base deleti
D19&20 transcript is 925 bp, D20&21 transcript is 832 bp and D21&22 transcrexon 20: a 2 bp deletion (Patient B, c2601-2602delAA)
and an 8 bp deletion (Patient C, c2568-2575delACCC
ACCA), all of which induce a reading frame-shift and dys-
trophin protein truncation, resulting in a DMD phenotype.
The mutations were conﬁrmed by sequencing genomic
DNA and RT-PCR amplicons (Supplementary Fig. 1)
and the aﬀect of the mutations on ESEs was assessed (Sup-
plementary Fig. 2). There are two alternative strategies
available to restore the reading-frame in each of these muta-
tions. Mutations in exon 51 can be corrected by skipping
exons 50&51 or exons 51&52, mutations in exon 20 are cor-
rectable by skipping exons 19&20 or 20&21.19 22
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duplication G, cocktails of oligomers targeted to exon
50&51 and 51&52 induced skipping of both exons at the
lowest concentration of 2.5 nM (Fig. 3). The exon 51&52
cocktail appeared marginally more eﬀective, demonstrated
by the reduced level of full-length transcript, compared to
the 50&51 cocktail (Fig. 3D and E).
The consequences of the small intra-exonic deletion
(2 and 8 bases) are illustrated in Fig. 3F, as are the two dual
exon skipping strategies to restore the reading frame
(Fig. 3G and H). In the cells carrying the 2 bp deletion in
exon 20, the cocktail targeting exons 19&20 induced skip-
ping of the two exons at 100 nM, but skipping could not
be detected in the cells treated at lower concentrations
(Fig. 3I). The cocktail targeting exons 20&21 showed highly
eﬃcient skipping, close to 100% of both exons were excised
at the lowest transfection concentration of 25 nM (Fig. 3J).
In the cells with the 8 bp deletion, skipping of exons 19&20
was 100% after AO transfection at 400–600 nM, however in19 22
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is 1074 bp and D20&21 is 832 bp.cells transfected with 200 nM of AO, skipping of both exons
was observed in 60% of transcripts, with intermediate tran-
scripts, lacking exon 19 or 20 only, also detectable
(Fig. 3K). Levels of exon skipping were reduced to approx-
imately 10–20% after transfection at 50 nM of AO, and
undetectable at 25 nM. Exon 20&21 skipping was also
highly eﬃcient and could be induced to approximately
90% by transfection at 50–600 nM, and a low level of skip-
ping could be detected at 25 nM (Fig. 3L).
3.3. Personalised strategies for selected splice-site mutations
A DMD patient was identiﬁed with a point mutation
(Patient D, c2804-2C>G) at the exon 22 acceptor splice site
(Fig. 4A). This base change altered the normal splice site
score from 1.3 to 9.7 and activated a cryptic splice site
with a score of 2.4. The retention of the last G nucleotide
from intron 21 shifted the reading frame to convert exon
22 into an in-frame exon. Employing conventional exon21 22
AG 
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exon 22 could be treated by the excision of exons 21&22
(Fig. 4B). However, in this case, the additional base at
the beginning of exon 22 allows the removal of exon 21
only to restore the reading frame (Fig. 4C). The two poten-
tial strategies to address this mutation were tested in MyoD
transformed ﬁbroblasts from the patient. Targeting a cock-
tail of AOs to exons 21&22 showed that this pair of exons
could not be eﬀectively removed at the concentrations
tested, and skipping of exon 21 only could be detected
(Fig. 4D). Targeting exon 21 alone showed eﬃcient
removal of this exon at all concentrations tested (Fig. 4E).
Another patient diagnosed with DMD was found to
carry a single base change (Patient E, c2623-3C>G), at
the acceptor splice site of exon 21. This mutation changed
the normal splice site score from 4.2 to 6.3, and created
an alternative splice site with a score of 3.1. This induced
retention of the last 2 AG nucleotides of intron 20 in the
mature dystrophin mRNA (Fig. 4F). The two conventional
exon-skipping strategies to remove the gene lesion and
restore the reading frame involve excision of exons 20&21
(Fig. 4G) or 21&22, with an example of robust exon skip-
ping of the former shown in Fig. 4I. As with the exon 22
mutation described earlier, removal of exons 21&22 was
not eﬃcient (data not shown). However, the retention of
the last 2 nucleotides of intron 20 would oﬀ-set the
frame-shifting loss of 2 bases if only exon 20 was excised,
presenting a third potential option to restore the reading
frame for this mutation (Fig. 4H). Surprisingly, targeting
only exon 20 also induced transcripts missing exons
20&21, however these are in-frame (Fig. 4J).
4. Discussion
DMD is a serious muscle wasting condition for which
there is no treatment. The application of splice switching
oligomers to remove or correct frame-shifting mutations
that would otherwise lead to premature termination of
translation has progressed from a concept to clinical trials.
Proof-of-concept has been demonstrated in animal models
and recently in DMD patients, with completion of Phase I
intramuscular studies and Phase I/IIa systemic studies with
two diﬀerent oligonucleotide analogues [5–8]. The DMD
mutation proﬁle and incidence will determine exon targets
for subsequent splice switching clinical trials, and these
studies must focus on single exon removal, due to the num-
ber of responsive patients and cost of safety and toxicology
validation required for each new oligomer [30]. Dual exon
skipping to restore dystrophin expression has been demon-
strated in animal models [3,12,31,32] and is technically fea-
sible, but will be further from the clinic. The targeting of
two or more exons in human dystrophin has been reported
by others using AO cocktails [22,29,33] or AOs joined by a
linker.
DMD is regarded as an orphan disease, with an esti-
mated 420,000 aﬀected individuals worldwide [34]. How-
ever, when further classifying amenable DMD mutationsinto subclasses, we suggest that exon skipping should be
regarded as a personalised genetic treatment. As such,
any strategies to implement exon skipping should be con-
sidered on a case-by-case basis, and it is important that
the simplest and most eﬀective exon skipping strategy for
each mutation be carefully considered. The factors that will
determine the most suitable strategy and AO sequence
include the following: Which AOs are the most eﬃcient
at excising the target exon(s) in vitro? Which strategy will
produce the most functional truncated dystrophin isoform,
determined by BMD patient data and transient inducible
mouse model [12]? What are the potential oﬀ-target eﬀects
of the AO treatment, including eﬀects related to AO chem-
istry and sequence dependant eﬀects? How many other
patients could potentially be treated by skipping the com-
bination of exons [30]?
This study reports DMD mutations that can be
addressed by multiple strategies to restore the reading
frame and facilitate translation of a BMD-like dystrophin
isoform. This includes intra-exonic mutations in exons 51
and 20. In these cases, the mutated exon must be excised
with either ﬂanking exon. The mutation in exon 51, was
marginally more eﬃciently addressed, at least in vitro, by
skipping of exon 51 + 52. This is in contrast to the result
in normal myogenic cells where exons 50 + 51 were more
eﬃciently removed. ESE analysis did not show any altera-
tions to ESEs as a result of the mutation, yet this is not
conclusive evidence that the exon 51 disease-causing vari-
ant does not inﬂuence splicing. We previously demon-
strated that a nonsense mutation in dystrophin exon 17
did not alter the eﬃciency of oligomers targeted to excise
exon 17, but did inﬂuence exon 18 skipping [29]. This sug-
gests subtle cross communication between exons during
splicing, and further emphasises the need for empirical
AO testing in patient-derived cells. In terms of the eﬀect
on the functionality of the resulting dystrophin isoform,
it is not yet clear if dystrophin lacking exon 50&51, and
therefore the whole of hinge 3 will be more functional than
dystrophin lacking exons 51&52 where part of hinge 3 is
retained. It has been reported that in-frame dystrophin
deletions involving hinge 3 have a milder phenotype com-
pared with other shorter deletions that do not involve that
domain [35].
In cells from the patients with small intra-exonic dele-
tions in exon, exons 20&21 were consistently removed
more eﬃciently than exons 19&20. This is in agreement
with the results obtained in normal myogenic cells. Both
these mutations did cause small changes in the predicted
ESE sites, but this does not appear to have aﬀected the eﬃ-
ciency of the AO cocktails. Again, the eﬀect on the func-
tionality of the resultant dystrophin must be considered.
In an AO induced transient mouse model, exons 19&20
could be removed from 100% of transcripts in the mouse
diaphragm, with no detectable detrimental eﬀects on the
muscle phenotype [12]. The Leiden DMD database con-
tains 2 patients lacking exons 19&20 [36,37], both are clas-
siﬁed as DMD however the mutation screening was
304 C.F. Adkin et al. /Neuromuscular Disorders 22 (2012) 297–305conducted using multiplex PCR and may not be fully infor-
mative [38]. One patient with a deletion of exons 20&21 is
classiﬁed as BMD (DMD mutation database on http://
www.dmd.nl), although detailed clinical data is not pub-
licly available for these patients.
We also report on single base changes that alter splicing
at particular exon boundaries and present unique opportu-
nities for simpler, alternative exon skipping strategies. In
these cases, additional factors should be considered, other
than which is the most eﬃcient strategy and which results
in the most functional dystrophin isoform.We have demon-
strated that for two splice site mutations an opportunity
exists to restore the reading frame by excision of a single
exon, rather than the two exons suggest by conventional
exon skipping strategies. For the exon 22 acceptor splice site
mutation, the results demonstrate that skipping both exons
21&22 is ineﬃcient in the patient’s cells, while skipping exon
21 alone is a much simpler strategy and is more eﬃcient
in vitro in patient cells. Some large in-frame DMD deletions
are associated with a mild phenotype, however this is
greatly dependent upon the location of the DMD mutation
[39,40]. In general, the loss of a smaller region of the dystro-
phin protein should confer greater functionality, and there-
fore a milder phenotype. In addition to the loss of exon 21
sequence, this strategy results in an isoleucine to valine
amino acid substitution. Both amino acids possess large,
non-polar, strongly hydrophobic side chains; hence the sub-
stitution could be predicted to have a minimal eﬀect on the
structure and function of the protein.
In normal myoblasts, skipping exon 20&21 or exon
21&22 was comparable, with the 20&21 cocktail proving
marginally more eﬃcient. In MyoD converted ﬁbroblasts
from the patient carrying the exon 21 splice site mutation,
exon 20&21 were eﬀectively removed by an AO cocktail.
Exon 20 was also eﬀectively excised on its own. In this case
the inserted bases at the beginning of exon 21 (AG) are
identical to the last two bases of exon 20, so excision of
exon 20 does not alter the remaining amino acid sequence.
Unexpectedly, it appears that the mutation facilitates skip-
ping of exon 21 when exon 20 only is targeted, possibly
because the exon 21 acceptor splice site is compromised.
However, as both these transcripts are in-frame and allow
dystrophin translation, targeting exon 20 only remains a
viable option for this patient, despite this unexpected eﬀect
on exon selection.
We propose a set of guidelines to be followed when deal-
ing with splice site mutations that may be amenable to splice
manipulation. The “minimalist” exon skipping strategies
will be more applicable to mutations that occur near exon
boundaries, and to minimise the possibility of encountering
in-frame stop codons, will be very dependent on the precise
position and nature of the mutation. Therefore, careful
analysis of the eﬀect of the mutation on splicing of the exon
is required and it must also be determined if the mutation
aﬀects the AO binding sites. Many exons are most eﬃciently
removed by an AO targeted near the 30 acceptor splice site
and mutations in this region would therefore disrupt AObinding, and it may be necessary to use sub-optimal AOs
that avoid the mutation, or design additional sequences spe-
ciﬁc to the mutation. Once these considerations have been
taken into account, the other factors that impact upon the
optimal strategy; eﬃcient removal of the target exon, func-
tionality of the resultant dystrophin, potential oﬀ-target
eﬀects, applicability to other DMD patients and cost-bene-
ﬁt analysis of the alternative strategies must be considered,
before the optimal strategy is selected.
5. Conclusion
As splice switching oligomer therapies progress through
early clinical studies, it will be necessary to demonstrate
unequivocal beneﬁts in response to the treatment and then
expedite application to the widest possible cohort of DMD
patients. We report DMD mutations that present multiple
exon skipping strategies to correct the reading frame. In
addition, we have shown that splice site mutations can
present unique opportunities that reduce the number of
exons that must be excised, producing a simpler, more eﬃ-
cient and less costly strategy that could potentially result in
a more functional dystrophin. This highlights the need to
carefully characterise all DMD mutations to determine if
they are suitable for treatment by exon skipping, and
detailed investigation may be required to determine which
will be the optimal strategy for each patient. This strength-
ens the case for splice-switching oligomers as a personalised
genetic treatment for DMD, and emphasises aspects that
should be considered as this therapy becomes available to
amenable patients.Acknowledgments
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